Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting

被引:13
|
作者
Townsend, Jeffrey P. [1 ,2 ,3 ,4 ,6 ]
Hassler, Hayley B. [1 ]
Dornburg, Alex [5 ]
机构
[1] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[2] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT USA
[3] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA
[4] Yale Univ, Program Microbiol, New Haven, CT USA
[5] Univ N Carolina, Dept Bioinformat & Genom, Charlotte, NC USA
[6] Yale Sch Publ Hlth, Dept Biostat, 135 Coll St, New Haven, CT 06510 USA
基金
美国国家科学基金会;
关键词
BNT162b2; mRNA-1273; mRNA vaccines; SARS-CoV-2 variant evolution; updated COVID-19 vaccine; vaccination schedule; ANTIBODY-RESPONSES; DURATION; COVID-19;
D O I
10.1002/jmv.28461
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
One of the most consequential unknowns of the COVID-19 pandemic is the frequency at which vaccine boosting provides sufficient protection from infection. We quantified the statistical likelihood of breakthrough infections over time following different boosting schedules with messenger RNA (mRNA)-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech). We integrated anti-Spike IgG antibody optical densities with profiles of the waning of antibodies and corresponding probabilities of infection associated with coronavirus endemic transmission. Projecting antibody levels over time given boosting every 6 months, 1, 1.5, 2, or 3 years yielded respective probabilities of fending off infection over a 6-year span of >93%, 75%, 55%, 40%, and 24% (mRNA-1273) and >89%, 69%, 49%, 36%, and 23% (BNT162b2). Delaying the administration of updated boosters has bleak repercussions. It increases the probability of individual infection by SARS-CoV-2, and correspondingly, ongoing disease spread, prevalence, morbidity, hospitalization, and mortality. Instituting regular, population-wide booster vaccination updated to predominant variants has the potential to substantially forestall-and with global, widespread uptake, eliminate-COVID-19.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
    Strengert, Monika
    Becker, Matthias
    Ramos, Gema Morillas
    Dulovic, Alex
    Gruber, Jens
    Juengling, Jennifer
    Luerken, Karsten
    Beigel, Andrea
    Wrenger, Eike
    Lonnemann, Gerhard
    Cossmann, Anne
    Stankov, Metodi, V
    Dopfer-Jablonka, Alexandra
    Kaiser, Philipp D.
    Traenkle, Bjoern
    Rothbauer, Ulrich
    Krause, Gerard
    Schneiderhan-Marra, Nicole
    Behrens, Georg M. N.
    EBIOMEDICINE, 2021, 70
  • [22] A short discussion about the SARS-CoV-2 mRNA-1273 vaccine
    Oronsky, Bryan
    Gruber, Harry E.
    Reiners, Wendy
    Reid, Tony R.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 104 : 532 - 533
  • [23] How to Deal With Vaccine Breakthrough Infection With SARS-CoV-2 Variants
    Guo, Ying
    Meng, Jun
    Liu, Caide
    Chen, Guosheng
    Chi, Yuhua
    Zheng, Shiliang
    Wang, Haixia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [24] Immune response scenario and vaccine development for SARS-CoV-2 infection
    Mohammad, Mai H. S.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 94
  • [25] Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection
    Mongin, Denis
    Buergisser, Nils
    Laurie, Gustavo
    Schimmel, Guillaume
    Vu, Diem-Lan
    Cullati, Stephane
    Courvoisier, Delphine Sophie
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [26] A Unique mRNA Vaccine Elicits Protective Efficacy against the SARS-CoV-2 Omicron Variant and SARS-CoV
    Guan, Xiaoqing
    Verma, Abhishek K.
    Wang, Gang
    Roy, Abhijeet
    Perlman, Stanley
    Du, Lanying
    VACCINES, 2024, 12 (06)
  • [27] An Analysis of SARS-CoV-2 Vaccine Reactogenicity: Variation by Type, Dose, and History, Severity, and Recency of Prior SARS-CoV-2 Infection
    Scher, Ann I.
    Berjohn, Catherine M.
    Byrne, Celia
    Colombo, Rhonda E.
    Colombo, Christopher J.
    Edwards, Margaret Sanchez
    Ewers, Evan C.
    Ganesan, Anuradha
    Jones, Milissa
    Larson, Derek T.
    Libraty, Daniel
    Lindholm, David A.
    Madar, Cristian S.
    Maldonado, Carlos J.
    Maves, Ryan C.
    Mende, Katrin
    Richard, Stephanie A.
    Rozman, Julia S.
    Rusiecki, Jennifer
    Smith, Alfred
    Simons, Mark
    Tribble, David
    Agan, Brian
    Burgess, Timothy H.
    Pollett, Simon D.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (07):
  • [28] An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants
    Kayesh, Mohammad Enamul Hoque
    Kohara, Michinori
    Tsukiyama-Kohara, Kyoko
    VIRUSES-BASEL, 2021, 13 (11):
  • [29] Myocardial Injury and Altered Gene Expression Associated With SARS-CoV-2 Infection or mRNA Vaccination
    Altman, Natasha L.
    Berning, Amber A.
    Saxon, Cara E.
    Adamek, Kylie E.
    Wagner, Jessica A.
    Slavov, Dobromir
    Quaife, Robert A.
    Gill, Edward A.
    Minobe, Wayne A.
    Jonas, Eric R.
    Carroll, Ian A.
    Huebler, Sophia P.
    Raines, Joshua
    Messenger, John C.
    Ambardekar, Amrut, V
    Mestroni, Luisa
    Rosenberg, Rachel M.
    Rove, Jessica
    Campbell, Thomas B.
    Bristow, Michael R.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (02): : 124 - 137
  • [30] Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines
    Hromic-Jahjefendic, Altijana
    Lundstrom, Kenneth
    Adilovic, Muhamed
    Aljabali, Alaa A. A.
    Tambuwala, Murtaza M.
    Serrano-Aroca, Angel
    Uversky, Vladimir N.
    AUTOIMMUNITY REVIEWS, 2024, 23 (03)